QIAGEN announced after the market close on March 29 that it offered 683 million Danish kroner (US$1.035 billion) to acquire the famous life science and molecular diagnostic company Exiqon in Denmark.
After discussions with Exiqon's board of directors earlier this year, QIAGEN has submitted a voluntary conditional public offer to buy all Exiqon shares at 18 DKK per share, compared to March 29 at Exiqon on NASDAQ. The closing price in Copenhagen is 41.7% higher than the closing price.
Exiqon is no stranger to everyone. This is a Danish company with about 100 employees. It has two big chunks of business: life sciences and diagnostics. In the life sciences, Exiqon provides flexible protocols for RNA molecules, and its products such as microRNAs and lncRNAs are well known. At the same time, Exiqon has partnered with pharmaceutical and diagnostic companies to develop new molecular diagnostic tests for early detection of disease.
Exiqon's fourth-quarter revenue increased 36% year-on-year to DKK 46.6 million, while net sales for the full year 2015 reached DKK 162 million. The company said it expects total revenue in 2016 to be in the range of 1.80-1.85 billion DKK, which is mainly driven by sales of products and services, but does not include OEM revenue.
If the offer is accepted by the shareholders, QIAGEN will also pay special fees, including financial and legal consulting fees, as well as transaction bonuses paid to senior management, for a total of approximately 25 million to 30 million DKK.
QIAGEN plans to issue a formal offer document within four weeks once approved by the Danish Financial Supervisory Authority. In a statement, Exiqon stated that its board of directors recommended shareholders to agree to the offer. QIAGEN intends to purchase all of Exiqon's shares to withdraw from the NASDAQ Copenhagen market.
QIAGEN said it expects the acquisition to expand its position in the RNA analysis market. Exiqon focuses on non-coding RNAs such as microRNAs and lncRNAs. Specifically, Exiqon offers sample preparation and analysis techniques, bioinformatics solutions, and a range of patented technologies, including the well-known Locked Nucleic Acid (LNA) technology, which greatly enhances the sensitivity of PCR, next-generation sequencing targeted enrichment and functional analysis. And specificity.
In other words, QIAGEN and the Danish company are quite fate. In 2013, QIAGEN acquired a Danish bioinformatics company, CLC Bio. CLC Bio develops and markets software to analyze genomic data from next-generation sequencers and traditional Sanger sequencers. Its product portfolio includes CLC Genomics Workbench, CLC Main Workbench and CLC Genomics Server.
China Extract Powder For Use As Dietary Supplement Extract Powder, Extract Powder Manufacturer
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.apipepdites.com